- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05423847
Triage UltraSound in Tb Endemic Regions (TrUST)
Point-of-care Ultrasound for the Diagnosis and Risk Stratification of Lower Respiratory Tract Infections in TB Endemic Regions: a Multicenter Prospective Cohort Study
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Design International multicentre prospective cohort study
Setting This study aims to explore the performance of POCUS in a pre-hospital setting in countries with different prevalences of HIV: South- Africa (high prevalence), Benin (low prevalence) and Mali (low prevalence).
Study procedures Pre-recruitment training Before initiating the study, participating clinicians will benefit from lung ultrasound (LUS) and POCUS protocols for extra pulmonary TB (FASH+ exam) training with a field expert. The participating clinicians are required to pass a final expert test before start of patient recruitment and to have a minimum of 20 supervised US.
Inclusion (Day 0) Patients inclusion will be performed over a period of 18 to maximum 24 months. Recruitment will stop before the anticipated end if the inclusion of 1000 patients is reached.
Clinical data Data collected include demographic characteristics (age, sex, occupation etc.), past medical history (previous TB, Coronavirus Disease (COVID), vaccination status, documented past episodes of COVID-19, HIV status,…), symptoms (respiratory symptoms, specific COVID-19 symptoms (from the Centers for Disease Control COVID checklist), specific pulmonary TB symptoms (from the CDC TB checklist) and routine clinical examination findings (vital parameters, oxygen saturation, lung auscultation,…).
Laboratory analyses
Analyses performed on site:
- HIV screening with a serial two rapid test algorithm as per World Health Organization (WHO) guidelines : Screening with Alere Determine combo®; if positive, confirmation by a second rapid test First Response® HIV 1-2-0, CD4 count and/or Viral load as per national guidelines.
- Sputum for GeneXpert Mycobacterium Tuberculosis (MTB)/rifampicine (RIF) assay
- Induced sputum for a new GeneXpert MTB assay if a routine spot and second morning GeneXpert MTB is negative and sputum quality was low (salivary) as per WHO consolidated guidelines
- Sputum for Gram stain and standard bacteriological culture
- Nasopharyngeal swab for Severe Acute Respiratory Syndrome Coronovirus (SARS-CoV-2) real-time polymerase chain reaction (RT-PCR) (Cepheid Xpert Xpress SARS-CoV-2) Since the additional diagnostic yield of mycobacterial culture is shown to be very low in adult patients with cough in Benin, it is reserved for GenXpert MTB/RIF resistant cases, specimens other than sputum (e.g. pleural effusions, where sensitivity of GeneXpert MTB/RIF is low) and patients with treatment failure. Mycobacterial culture will be done on solid medium (Löwenstein-Jensen).
Analyses performed retrospectively on stored samples:
- Nasopharyngeal swab: PCR for influenza
- Sputum: syndromic molecular panel targeting influenza and atypical bacteria. Radiological examinations
- Chest X-Ray (CXR) - face: digital format will be stored
- LUS exam using a standard point-of-care ultrasound device (ultrasound-on-a-chip), LUS will be recorded according to a standard 12-point acquisition protocol with 4 additional apical sites (2 subclavicular and 2 axillary) for improved TB detection.
- This involves scanning both apexes, the anterior and posterior apexes, anterior superior, anterior inferior, posterior superior, posterior inferior and lateral thorax regions
- FASH plus exam using a standard point-of-care ultrasound device. The FASH plus protocol will be performed in a standardized manner as previously described.
All US images captured will be digitally recorded and transferred via a secured internet connection along with relevant metadata to a secure server for storage. For study quality control purposes, the quality of the image and the interpretation of a random sample of images will be evaluated retrospectively by an experienced radiologist.
Clinician-evaluated LUS and FASH All LUS and FASH exams will be read by 2 independent readers blinded to patients diagnosis and outcome. A third reader will solve discrepancies between the two readers. They will fill in a standardized LUS and FASH report.
AI-evaluated LUS and FASH The US images will be further used for secondary studies developing deep learning algorithms for LUS and FASH diagnosis.
Follow-up (D7 and D28) Patients will receive a follow-up phone call by the study nurse on day 7 and day 28. Data on the clinical evolution are collected: hospitalization, non-invasive ventilation, intubation, death.
Follow-up of TB treatment failures and deaths until D180 TB patients will be followed in the national TB register and treatment failures will be recorded at 6 months of treatment (according to national guidelines).
Deaths will be recorded until D180 as well.
Tipo de estudo
Inscrição (Antecipado)
Contactos e Locais
Contato de estudo
- Nome: Noémie Boillat-Blanco, MD-PhD, PD
- Número de telefone: +41 (0)79 556 16 86
- E-mail: noemie.boillat@chuv.ch
Estude backup de contato
- Nome: Veronique Suttels, MD
- Número de telefone: +229 97 44 87 82
- E-mail: veronique.suttels@outlook.com
Locais de estudo
-
-
Atlantic
-
Cotonou, Atlantic, Benim
- Recrutamento
- CNHUPPC
-
Contato:
- Gildas Agodokpessi, Prof
- E-mail: aggildas@yahoo.fr
-
-
-
-
-
Bamako, Mali
- Ainda não está recrutando
- CHU point G
-
Contato:
- Khadidia Ouattara, MD
- E-mail: zankhadi@gmail.com
-
-
-
-
-
Acornhoek, África do Sul
- Recrutamento
- Wits Rural University
-
Contato:
- Jacques Du Toit
- E-mail: jacques.dutoit1@wits.ac.za
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
- Benin: 6'500 cumulative total detected and declared COVID-19 cases since march 2020 to date (NB true COVID-19 incidence unknown due to undertesting), TB incidence 55/100'000/year, low HIV (prevalence < 2%)
- South Africa: 1,522'697 cumulative total detected and declared COVID-19 cases since march 2020 to date TB incidence 615/100.000/year, high HIV (prevalence approximately 20%)
- Mali: 30'420 cumulative total detected and declared COVID-19 cases since march 2020 to date (NB true COVID-19 incidence unknown due to undertesting), TB incidence 52/100'000/year, low HIV (prevalence < 2%)
Descrição
Inclusion Criteria:
- Age ≥18 years
- Suspicion of lower respiratory tract infection (defined as presence of cough with at least one of the following: fever, dyspnea/tachypnea, sputum production, chest pain, hemoptysis or cachexia)
Exclusion Criteria:
- Cough/dyspnea from a definite non-infectious origin (cardiac, asthmatic...)
- Inability to cooperate with ultrasound procedure
- Inability to sign informed consent (third witness procedure available for illiterate patients)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
---|---|
Benin1
Benin urban recruitment site National teaching hospital for tuberculosis, outpatient emergency department
|
POCUS of lungs, pericardium and abdomen
|
Mali1
Mali urban recruitment site University Hospital Bamako, outpatient emergency department
|
POCUS of lungs, pericardium and abdomen
|
South-Africa1
South-Africa rural recruitment site 1 Tintswalo hospital, outpatient emergency department
|
POCUS of lungs, pericardium and abdomen
|
South-Africa2
South-Africa rural recruitment site 2 Zithulele hospital, outpatient emergency department
|
POCUS of lungs, pericardium and abdomen
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Sensitivity of LUS for the detection of TB
Prazo: 18 to 24 months
|
For LUS, each lung quadrant will be scored using a 6 feature LUS score (modified Soldati score) ranging from 1 (aerated lung), 2 (interstitial syndrome), 3 (sub centimeter pleural lesions), 4 (lung consolidation), 5 (pleural effusion) to 6 (pneumothorax).
Sensitivity of LUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards
|
18 to 24 months
|
Specificity of LUS for the detection of TB
Prazo: 18 to 24 months
|
For LUS, each lung quadrant will be scored using a 6 feature LUS score (modified Soldati score) ranging from 1 (aerated lung), 2 (interstitial syndrome), 3 (sub centimeter pleural lesions), 4 (lung consolidation), 5 (pleural effusion) to 6 (pneumothorax).
Sensitivity of LUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards
|
18 to 24 months
|
Sensitivity of FASH PLUS for the detection of TB
Prazo: 24 to 36 months
|
For the pericardial and abdominal ultrasound, a score according to the FASH PLUS protocol will be attributed ranging from 0 (no pathology) to 6 (presence of pericardial effusion, abdominal adenopathies, pleural effusion, splenic lesions, hepatic lesions, ascites).
Sensitivity of FASH PLUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards.
|
24 to 36 months
|
Specificity of FASH PLUS for the detection of TB
Prazo: 24 to 36 months
|
For the pericardial and abdominal ultrasound, a score according to the FASH PLUS protocol will be attributed ranging from 0 (no pathology) to 6 (presence of pericardial effusion, abdominal adenopathies, pleural effusion, splenic lesions, hepatic lesions, ascites).
Specificity of FASH PLUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards.
|
24 to 36 months
|
Sensitivity of combined LUS and FASH PLUS features for the detection of TB
Prazo: 24 to 36 months
|
Sensitivity of combined LUS and FASH PLUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards.
|
24 to 36 months
|
Specificity of combined LUS and FASH PLUS features for the detection of TB
Prazo: 24 to 36 months
|
Specificity of combined LUS and FASH PLUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards.
|
24 to 36 months
|
Sensitivity of AI-interpreted LUS for the detection of TB
Prazo: 24 to 36 months
|
LUS images will be scored binary by microbiological-label trained algorithms as TB or not TB.
Prediction: Sensitivity of AI-assisted interpretation LUS for the detection of TB using microbiological tests as reference standards
|
24 to 36 months
|
Specificity of AI-interpreted LUS for the detection of TB
Prazo: 24 to 36 months
|
LUS images will be scored binary by microbiological-label trained algorithms as TB or not TB.
Prediction: Specificity of AI-assisted interpretation LUS for the detection of TB using microbiological tests as reference standards
|
24 to 36 months
|
Sensitivity of AI-interpreted FASH PLUS for the detection of TB
Prazo: 24 to 36 months
|
FASH PLUS images will be scored binary by microbiological-label trained algorithms as TB or not TB.
Prediction: Sensitivity of FASH PLUS for the detection of TB using microbiological tests as reference standards
|
24 to 36 months
|
Specificity of AI-interpreted FASH PLUS for the detection of TB
Prazo: 24 to 36 months
|
FASH PLUS images will be scored binary by microbiological-label trained algorithms as TB or not TB.
Prediction: Specificity of FASH PLUS for the detection of TB using microbiological tests as reference standards
|
24 to 36 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Qualitative assessment using semi-structured interviews (based on grounded theory methods) with end users of the barriers and facilitators of the implementation of POCUS
Prazo: 12 months
|
Qualitative assessment using semi-structured interviews (based on grounded theory methods) with end users of the barriers and facilitators of the implementation of POCUS to assess its feasibility, sustainability and acceptability
|
12 months
|
Qualitative assessment using semi-structured interviews (based on grounded theory methods) with end users of the barriers and facilitators of the implementation of AI clinical decision support
Prazo: 12 months
|
Qualitative assessment using semi-structured interviews (based on grounded theory methods) with end users of the barriers and facilitators of the implementation of AI clinical decision support to assess its feasibility, sustainability and acceptability
|
12 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Mary-Anne Hartley, MD-PhD, Ecole Polytechnique Fédérale de Lausanne
- Investigador principal: Noémie Boillat Blanco, MD-PhD, Lausanne University Hospital
- Investigador principal: Veronique Suttels, MD, Lausanne University Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CGRB11362
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .